Usefulness of suppression of ventricular arrhythmia by biventricular pacing in severe congestive cardiac failure

American Journal of Cardiology

Volumn 86, Issue 2, 2000, Pages 231-233

  Walker, Stuart ^a   Levy, Terry M ^a   Rex, Steve ^a   Brant, Sandra ^a   Allen, Jon ^a   Ilsley, Charles J D ^a   Paul, Vincent E ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTIFICIAL HEART PACEMAKER; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HEART ATRIUM FIBRILLATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE PACING; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; SINGLE BLIND PROCEDURE; SINUS RHYTHM;

ADULT; AGED; ARRHYTHMIA; CARDIAC PACING, ARTIFICIAL; CROSS-OVER STUDIES; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SINGLE-BLIND METHOD;

EID: 0034048502     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)00865-1     Document Type: Article

References (16)

1. Kjekshus J. Arrhythmias and mortality in congestive heart failure. Am J Cardiol. 65:1990;42I-48I.
2. Francis G.S. Development of arrhythmias in the patient with congestive heart failure pathophysiology, prevalence and prognosis. Am J Cardiol. 57:1986;3B-7B.
3. Cohn J.N., Johnson G.R., Shabetai R., Loeb H., Tristani F., Rector T., Smith R., Fletcher R. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. Circulation. 87:(suppl V):1993;VI5-V16.
4. Preliminary report effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 321:1989;406-412.
5. Cairns J.A., Connolly S.J., Roberts R., Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet. 349:1997;675-682.
6. Julian D.G., Camm A.J., Frangin G., Janse M.J., Munoz A., Schwartz P.J., Simon P. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet. 349:1997;667-674.
7. Doval H.C., Nul D.R., Grancelli H.O., Perrone S.V., Bortman G.R., Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet. 344:1994;493-498.
8. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 337:1997;1576-1583.
9. Auricchio A., Stellbrink C., Sack S., Block M., Vogt J., Bakker P., Mortensen P., Klein H. The pacing therapies for congestive heart failure (PATH-CHF) study rationale, design, and endpoints of a prospective randomised multicentre study. Am J Cardiol. 83:1999;130D-135D.
10. Gras D., Mabo P., Tang T., Luttikuis O., Chatoor R., Pederson A.K., Tscheliessnigg H.H., Deharo J.C., Puglisi A., Silvestre J., Kimber S., Ross H., Ravazzi A., Paul V., Skehan D. Multi-site pacing as a supplemental treatment of congestive heart failure preliminary results of the Medtronic Inc. InSync study. Pacing Clin Electrophysiol. 21:1998;2249-2255.
11. Feldman A.M., Bristow M.R., Parmley W.W., Carson P.E., Pepine C.J., Gilbert E.M., Strobeck J.E., Hendrix G.H., Powers E.R., Bain R.P. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med. 329:1993;149-155.
12. Krell M.J., Kline E.M., Bates E.R., Hodgson J.M., Dilworth L.R., Laufer N., Vogel R.A., Pitt B. Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J. 112:1986;787-791.
13. Packer M., Carver J.R., Rodeheffer R.J., Ivanhoe R.J., DiBianco R., Zeldis S.M., Hendrix G.H., Bommer W.J., Elkayam U., Kukin M.L. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 325:1991;1468-1475.
14. Uretsky B.F., Jessup M., Konstam M.A., Dec G.W., Leier C.V., Benotti J., Murali S., Herrmann H.C., Sandberg J.A. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation. 82:1990;774-780.
15. Xamoterol in severe heart failure. Lancet. 336:1990;1-6.
16. Kindermann M., Frohlig G., Doerr T., Schieffer H. Optimizing the AV delay in DDD pacemaker patients with high degree AV block mitral valve Doppler versus impedance cardiography. Pacing Clinl Electrophysiol. 20:1997;2453-2462.